Funded Tech Companies
SemaThera
Looking for the VC firms that invested in SemaThera? Senju Pharmaceutical and AmorChem put venture money into this innovative biopharmaceutical company.
Company Overview
Company Name
SemaThera
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
1 Westmount Sq. 800
Montreal QC, H3Z 2P9
Canada
Montreal QC, H3Z 2P9
Canada
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
SemaThera develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). SEMA 3A is a soluble protein that promotes vascular leakage and contributes to diabetes-related macular edema.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
3/28/2018
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Garth Cumberlidge
Chief Operating Officer
Veronique Bougie
Chief Scientific Officer
Michael Sapieha
Company Investors
- Senju Pharmaceutical (Mitsuyoshi Azuma)
- AmorChem (Elizabeth Douville)
Browse more funded tech companies:
Share this article
About Our VC Transaction Database
The company data above is provided by VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs